FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: Possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo

British Journal of Dermatology

Volumn 153, Issue 3, 2005, Pages 498-505

  Lan, C C E ^a   Chen, G S ^a   Chiou, M H ^a   Wu, C S ^b   Chang, C H ^c   Yu, Hsin Su ^d  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

FK506; Keratinocyte; Melanoblast; Melanocyte; Tacrolimus; Vitiligo

Indexed keywords

GELATINASE A; GELATINASE B; STEM CELL FACTOR; TACROLIMUS;

ARTICLE; CELL CULTURE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; KERATINOCYTE; MELANOCYTE; MELANOGENESIS; PATHOGENESIS; PRIORITY JOURNAL; SKIN PIGMENTATION; VITILIGO;

ADULT; CELL MOVEMENT; CELL PROLIFERATION; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, DRUG; GROWTH SUBSTANCES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATINOCYTES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANINS; MELANOCYTES; OINTMENTS; STEM CELL FACTOR; STIMULATION, CHEMICAL; TACROLIMUS; VITILIGO;

EID: 24344477170     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06739.x     Document Type: Article

References (54)

1. Kovac SO. Vitiligo. J Am Acad Dermatol 1998; 38:647-66.
2. Naughton GK, Reggiardo D, Bystryn JC. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986; 15:978-81.
3. Norris DA, Kissinger RM, Naughton GM, Bystryn JC. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 1988; 90:783-9.
4. Jimbow K, Chen H, Park JS, Thomas PD. Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase related protein in vitiligo. Br J Dermatol 2001; 133:55-65.
5. Ivanova K, Le Poole IC, Gerzer R et al. Effects of nitric oxide on the adhesion of human melanocytes to extracellular matrix components. J Pathol 1997; 183:469-76.
6. Schallreuter KU, Wood JM, Pittelkow MR et al. Increased monoaminooxidase activity in the epidermis of patients with vitiligo. Arch Dermatol Res 1996; 288:11-13.
7. Njoo MD, Spuls PI, Bos JD et al. Nonsurgical repigmentation therapies in vitiligo. Arch Dermatol 1998; 134:1532-40.
8. Mandel AS, Haberman JF, Pawlowski D, Goldstein E. Non PUVA nonsurgical therapies for vitiligo. Clin Dermatol 1997; 15:907-19.
9. Ortel B, Alge C, Pandy A. Phototherapeutic options for vitiligo. In: Dermatological Phototherapy and Photodiagnostic Methods (Krutmann J, Honigsmann H, Elmets CA, Bergstresser PR, eds). Heidelberg: Springer-Verlag, 2001; 135-61.
10. Fitzpatrick TB. Mechanisms of photochemotherapy of vitiligo. Arch Dermatol 1997; 133:1591-2.
11. Yu HS, Wu CS, Yu CL et al. Helium-neon laser irradiation stimulates migration and proliferation in melanocytes and induces repigmentation in segmental type vitiligo. J Invest Dermatol 2003; 120:56-64.
12. Staricco RG. Activation of amelanotic melanocytes in the outer root sheath of the hair follicle following ultraviolet exposure. J Invest Dermatol 1962; 39:163-4.
13. Cui J, Shen LY, Wang GC. Role of hair follicles in the repigmentation of vitiligo. J Invest Dermatol 1991; 97:410-16.
14. Kawa Y, Ito M, Ono H et al. Stem cell factor and/or endothelin-3 dependent immortal melanoblast and melanocyte populations derived from mouse neural crest cells. Pigment Cell Res 2000; 13 (Suppl. 8):73-80.
15. Ooka S, Kawa Y, Ito M et al. Establishment and characterization of a mouse neural crest derived cell line (NCCmelan5). Pigment Cell Res 2001; 14:268-74.
16. Reitamo S, Wollenberg A, Schopf E et al. Safety and efficacy of one year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000; 136:999-1006.
17. Hanifin JM, Ling MR, Langley R et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001; 44 (Suppl.):S28-38.
18. Peller A, Eichenfield LF, Leung DYM et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44 (Suppl.):S47-57.
19. Grimes PE, Soriano T, Dytoe M. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47:789-91.
20. Tanghetti EA. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis 2003; 71:158-62.
21. Travis LB, Weinberg JM, Silverberg NB. Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol 2003; 139:571-4.
22. Lepe V, Moncada B, Castanedo-Cazares JP et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobestasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139:581-5.
23. Zabawski EJ, Costner M, Cohen JB et al. Tacrolimus: pharmacology and therapeutic uses in dermatology. Int J Dermatol 2000; 39:721-7.
24. Skaehill PA. Tacrolimus in dermatologic disorders. Ann Pharmacother 2001; 35:582-8.
25. Cather JC, Abramovits W, Menter A. Cyclosporine and tacrolimus in dermatology. Dermatol Clin 2001; 19:119-37.
26. Lan CCE, Kao YH, Huang SM et al. FK506 independently upregulates transforming growth factor β and downregulates inducible nitric oxide synthase in cultured human keratinocytes: possible mechanisms of how tacrolimus ointment interacts with. Br J Dermatol 2004; 151:679-84.
27. Grimes PE, Morris R, Avaniss-Aghajani E et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004; 51:52-61.
28. Yu HS, Kao CH, Yu CL. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo. J Invest Dermatol 1993; 100:823-8.
29. Imokawa G, Yada Y, Miyagish M. Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes. J Biol Chem 1992; 267:24675-80.
30. Hu DN, McCormick SA, Orlow SJ et al. Melanogenesis by human uveal melanocytes in vitro. Invest Ophthal Vis Sci 1995; 36:931-8.
31. Horikawa T, Norris DA, Yohn JJ et al. Melanocyte mitogens induce both melanocyte chemokinesis and chemotaxis. J Invest Dermatol 1995; 104:256-9.
32. Woessner JF. Quantification of matrix metalloproteinases in tissue samples. Methods Enzymol 1995; 248:510-28.
33. Yarr M, Gilchrest BA. Human melanocyte growth and differentiation: a decade of new data. J Invest Dermatol 1991; 97:611-17.
34. Jimbow K, Quevedo WC, Prota G, Fitzpatrick TB. Biology of melanocytes. In: Dermatology in General Medicine (Freedberg IM, Eisen AZ, Wolff K et al., eds), 5th edn. New York: McGraw-Hill, 1999: 192-219.
35. Moretti S, Spallanzani A, Amato L et al. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002; 15:87-92.
36. Bohm M, Moellmann G, Cheng E et al. Identification of p90RSK as the probable CREB-Ser133 kinase in human melanocytes. Cell Growth Differ 1995; 6:291-302.
37. Moellmann G, Halaban R. Growth factor receptors and signal transduction regulating the proliferation and differentiation of melanocytes. In: The Pigmentary System: Physiology and Pathophysiology (Nordlund JJ, Boissy RE, Hearing VJ, King RA, eds). New York: Oxford University Press, 1998: 135-49.
38. Longley BJ, Morganroth GS, Tyrrell L et al. Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis. N Engl J Med 1993; 328:1302-7.
39. Hamann K, Haas N, Grabbe J, Czarnetzki BM. Expression of stem cell factor in cutaneous mastocytosis. Br J Dermatol 1995; 133:203-8.
40. Zsebo KM, Williams DA, Geissler EN et al. Stem cell factor is encoded at the S1 locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990; 63:213-24.
41. Costa JJ, Demetri GD, Harrist TJ et al. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 1996; 183:2681-6.
42. Kunisada T, Lu SZ, Yoshida H et al. Mouse cutaneous mastocytosis and epidermal melanocytosis induced by keratinocyte expression of transgenic stem cell factor. J Exp Med 1998; 187:1565-73.
43. Baba H, Uchiwa H, Watanabe S. UVB irradiation increases the release of SCF from human epidermal cells. J Invest Dermatol 2005; 124:1075-7.
44. Tiefenthaler M, Hofer S, Ebner S et al. In vitro treatment of dendritic cells with tacrolimus: impaired T-cell activation and IP-10 expression. Nephrol Dial Transplant 2004; 19:553-60.
45. Norris DA, Horikawa T, Morelli J. Melanocyte destruction and repopulation in vitiligo. Pigment Cell Res 1994; 7:193-203.
46. Petersen MJ, Woodley DT, Stricklin GP, O'Keefe EJ. Constitutive production of procollagenase and collagenase inhibitor by human keratinocytes in culture. J Invest Dermatol 1989; 92:156-9.
47. Petersen MJ, Woodley DT, Stricklin GP, O'Keefe EJ. Enhanced synthesis of collagenase by human keratinocytes cultured on type I or type IV collagen. J Invest Dermatol 1990; 94:341-6.
48. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997; 91:439-42.
49. Parks WC. The production, role, and regulation of matrix metalloproteinases in the healing epidermis. Wounds 1995; 7:A23-7.
50. Vaalamo M, Mattila L, Johansson N et al. Distinct populations of stromal cells express collagenase 3 and collagenase 1 in chronic ulcers but not in normally healing wounds. J Invest Dermatol 1997; 109:96-101.
51. Muller BM. Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. Curr Top Microbiol Immunol 1996; 213:65-80.
52. Lei TC, Vieira WD, Hearing VJ. In vitro migration of melanoblasts requires matrix metalloproteinase-2: implications to vitiligo therapy by photochemotherapy. Pigment Cell Res 2002; 15:426-32.
53. McCawley LJ, O'Brien P, Hudson LG. Epidermal growth factor (EGF) and scatter factor/hepatocyte growth factor mediated keratinocyte migration is coincidal with induction of matrix metalloproteinase (MMP)-9. J Cell Physiol 1998; 176:255-6.
54. Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg 2004; 30:130-5.